Free Sale Certificate Requirements for Myanmar Registration

1. Key takeaways

The Free Sale Certificate (FSC) is one of the core documents in the Myanmar medical device registration dossier, and its function is to confirm that the device is legally sold in its country of manufacture. The document must be issued by the competent authority of the country of manufacture.

GRZAN note: the Myanmar FDA’s scrutiny of the FSC focuses not on whether the document exists but on three consistencies — (1) whether the product name and models match the application; (2) whether the manufacturer name and address match the letter of authorisation; (3) whether the document is within the validity period accepted by the Myanmar FDA. In practice, an FSC is usually expected to be valid within 12 months of issuance, but the specific acceptance period must be confirmed with the Myanmar FDA as current practice, and this article does not reach a definitive conclusion. Planning to the shorter reading while asking for the authoritative answer is the only safe combination, because a document that expires during review cannot simply be patched with an explanatory letter.

2. Legal basis

3. Expert insights

Insight 1: the object of proof of the FSC is legal sale in the country of manufacture, not the quality of the product itself. This distinction determines that the FSC cannot substitute for technical documentation, risk management documents or test reports. Companies should position the FSC as evidence of market access standing, not as evidence of quality. Conflating the two leads teams to under-invest in the technical file while over-polishing a document that only ever answers one narrow question.

Insight 2: the three consistencies are the main cause of formality-review rejections. The product name, models, manufacturer name and address must correspond word for word across the FSC, the letter of authorisation and the company registration documents. Even a spelling difference can trigger a request for clarification, so the comparison must be done character by character, not by eye. Variations in legal suffixes, address formats and transliterations are the most common sources of mismatch between documents issued in different countries.

Insight 3: the 12-month validity period is a practical estimate and must be confirmed case by case. Public sources state the acceptance period in slightly different terms. When scheduling a project, companies should reserve time to renew the FSC rather than planning against the boundary of the period. A certificate requested early in the project often arrives while the dossier is still incomplete, and by the time the submission is ready the clock on the FSC may already have consumed most of its margin.

Insight 4: the counterfeit consumables problem has raised the intensity of document review. The Myanmar FDA has strengthened its scrutiny of FSCs and notarised documents in response to the counterfeit medical consumables problem. This means that the authenticity and verifiability of documents matter more than ever, and documents that cannot be independently verified by the authority carry real rejection risk. Notarisation and legalisation, where available, directly serve this verifiability expectation.

Insight 5: the FSC forms a cross-referencing chain with the other dossier documents. Consistency among the FSC, the letter of authorisation, the company registration documents and the label specimens is the main lever reviewers use to judge the credibility of an application. Treating the dossier as one interconnected set of statements, rather than a folder of independent papers, is the mindset that prevents clarification rounds. Each document answers a different question, but they must all tell the same story about the same product.

4. Practical recommendations

• Complete the three-consistency check before submission. Build a field-by-field comparison table covering the FSC, the letter of authorisation and the company registration documents.
• Schedule FSC renewals against the shorter reading of the period. Keep generous margins rather than cutting the validity boundary close.
• When obtaining the FSC, confirm the issuing power of the authority in the country of manufacture. Make sure the document can be verified by the Myanmar FDA.
• Obtain separate FSCs for multi-manufacturer situations. Match each product to each manufacturer one to one.
• Enter the consistency comparison table into the registration ledger. This allows it to be reused at renewal and at any variation.

5. Verification checklist

• □ An FSC issued by the competent authority of the country of manufacture has been obtained
• □ The consistency of product names and models has been checked
• □ The consistency of the manufacturer name and address has been checked
• □ It has been confirmed that the document is within the validity period accepted by the Myanmar FDA
• □ A comparison table between the FSC and the letter of authorisation has been established
• □ It has been confirmed that the issuing authority can be verified by the Myanmar FDA
• □ The consistency comparison table has been entered into the registration ledger

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com